Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)

    This grant supports research on population approaches to reducing alcohol-related cancer risk, focusing on awareness, social norms, alcohol policies, and interventions, with particular interest in addressing various levels of alcohol consumption and underserved minority populations.

    Browse similar grants
    Cancer Research Grants 2026
    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: National Institutes of Health

    Due Dates: January 7, 2027 (Current closing date)

    Funding Amounts: No budget cap; budgets must reflect project needs; up to 5 years

    Summary: Supports interdisciplinary, population-level research to reduce alcohol-related cancer risk through communication, social norms, policy, and multilevel interventions.

    Key Information: Cancer prevention expertise is required; studies solely developing or testing individual-level interventions will not be reviewed.


    Description

    This NIH R01 program, supported by the National Cancer Institute (NCI) and National Institute on Alcohol Abuse and Alcoholism (NIAAA), funds interdisciplinary population approaches to reducing alcohol-related cancer risk. It supports research on awareness of the alcohol–cancer relationship, social norms surrounding consumption, alcohol policy development and evaluation, and the development, testing, and implementation of population-level interventions.

    Studies may address any consumption level, from light drinking to heavy drinking and alcohol use disorder, across cancer prevention and survivorship. Applications addressing multiple consumption levels are of particular interest. The program encourages understudied topics and attention to populations experiencing cancer and alcohol-related disparities, including American Indian and Alaska Native populations. Research may involve adults, adolescents, or cancer patients and survivors. Clinical trials are optional, and cancer incidence or mortality endpoints are not required.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.